home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc. From 03/23/22

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Website: xortx.com
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

CALGARY, Alberta, March 23, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney diseas...
XRTX - XORTX Therapeutics files application in Canada for pharmacokinetics study

XORTX Therapeutics (NASDAQ:XRTX) said it submitted a clinical trial application to Health Canada for a XRX-OXY-101 bridging pharmacokinetics study to support a future clinical program in Autosomal Dominant Polycystic Kidney Disease (ADPKD). "While only several months in duration, this XRX-OXY...

XRTX - XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study

CALGARY, Alberta, March 14, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - XORTX Moving to the Next Level - Phase 3 Clinical Trials

e Research Corp. ( www.eresearch.com ) published a 25-page update Equity Research Report on XORTX Therapeutics Inc. (TSXV:XRTX | NASDAQ:XRTX | FSE:ANU) pertaining to its recent financings to “set the stage” for the initiation of late-stage clinical trials of therap...
XRTX - XORTX Provides Corporate Update

CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease...

XRTX - XORTX Announces Appointment of Chief Technology Officer

CALGARY, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease...

XRTX - XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

CALGARY, Alberta, Jan. 10, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease...
XRTX - MedAvail, Altamira Therapeutics leads healthcare gainers; Chembio Diagnostics, Gamida Cell among major losers

Gainers: MedAvail (NASDAQ:MDVL) +17%, Altamira Therapeutics (NASDAQ:CYTO) +17%, Orchard Therapeutics (NASDAQ:ORTX) +10%,Biofrontera (NASDAQ:BFRI) +9%, XORTX Therapeutics (NASDAQ:XRTX) +7%. Losers: Chembio Diagnostics (NASDAQ:CEMI) -16%, Gamida Cell (NAS...

XRTX - XORTX Reports Annual & Special Meeting Results

CALGARY, Alberta, Dec. 21, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease...

XRTX - XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

CALGARY, Alberta, Dec. 21, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease...
Previous 10 Next 10